Trial Profile
A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2022
Price :
$35
*
At a glance
- Drugs HIL 214 (Primary) ; Aluminium hydroxide; Monophosphoryl lipid A
- Indications Norovirus infections
- Focus Pharmacodynamics
- Sponsors Takeda
- 20 Jul 2022 According to a HilleVax media release, the company anticipates presenting data from this trial at a future medical meeting.
- 20 Jul 2022 Results published in the HilleVax Media Release.
- 08 Dec 2021 Status changed from active, no longer recruiting to completed.